Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





First-Ever Clinical T-Cell Based Test for Patients Confirms Recent or Prior COVID-19 Infection

By HospiMedica International staff writers
Posted on 01 Mar 2021
Adaptive Biotechnologies Corporation (Seattle, WA, USA) has launched T-Detect COVID, the first clinical T-cell based test to confirm recent or prior COVID-19 infection.

Knowledge of prior COVID-19 infection is critically important for those who believe they may have been infected with the virus but have not been able to confirm a diagnosis. More...
Until now, antibody tests have been the primary way to determine recent or prior COVID-19 infection. T-cell tests take an entirely new approach to determine prior infection by looking at a different but equally important part of our immune system, the T cell. In the setting of COVID-19, T-cell responses arise earlier than antibodies and persist in the blood for longer.

In real-world studies, the first-in-class T-Detect COVID test outperformed leading antibody tests. Patients can order T-Detect COVID online at www.t-detect.com by answering a few eligibility questions through a secure portal. A virtual provider will authorize a prescription and patients can have their blood drawn by a mobile phlebotomist at their home or they can visit one of nearly 2,000 Labcorp patient service centers. Patients will receive an email notification when their results are available, and they can view them via a secure portal. Patients ordering T-Detect COVID have the opportunity to contribute to ongoing research to further the understanding of T cell-based immunity to COVID-19. This is particularly important as scientists work to define immunity and establish correlates of protection to SARS-CoV-2, the virus that causes COVID-19, resulting from natural infection or vaccination. T-Detect is currently under review by the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).

“T-Detect COVID is the first T-cell test for patients and the first product resulting from Adaptive’s TCR-Antigen Map collaboration with Microsoft,” said Adaptive Biotechnologies Chief Executive Officer, Chad Robins. “By mapping the human immune response to COVID-19, we have developed a simple blood-based clinical test to help detect recent or prior infections from our T cells. This approach will be scaled for more accurate and early diagnosis of many infectious diseases, autoimmune disorders and cancer.”

Related Links:
Adaptive Biotechnologies Corporation


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.